Figure 1.
Change from baseline over 52 weeks in DAS28-ESR in patients with moderate-to-severe rheumatoid arthritis initially randomised to MSB11456 or EU-approved tocilizumab and in those rerandomised from EU-approved tocilizumab to MSB11456 at week 24, ITT analysis set. DAS28-ESR, Disease Activity Score-28 Joint erythrocyte sedimentation rate; EU, European Union; ITT, intention to treat.